Trex Bio Inc TRXB

$TRXB gogo

$TRXB 👀

$TRXB Alexandria Venture Investments, a major TRex Bio shareholder, purchased 178,571 shares at $14.00 each, investing approximately $2.5 million. The transaction increased Alexandria Venture Investments’ holdings by 15.29% to 1,346,501 shares, valued at roughly $18.85 million, according to an SEC filing.

TRex Bio, a South San Francisco-based clinical-stage biotechnology company, completed its initial public offering of 8,333,334 common shares at $14 per share, generating approximately $116.7 million in gross proceeds before underwriting discounts, commissions and other expenses. All shares were sold by the company, and its stock now trades on the Nasdaq Global Select Market. J.P. Morgan, Evercore ISI, Cantor and Stifel acted as lead book-running managers, while Wedbush PacGrow served as an additional bookrunner. The company’s SEC registration statement became effective on October 8, 2026, under filing number 333-299018. TRex Bio focuses on the biology of tissue-resident regulatory T cells, which help control immune responses. Its research aims to develop targeted immunoregulatory therapies for autoimmune and inflammatory diseases, addressing conditions in which the immune system becomes overactive or attacks the body’s own tissues. $TRXB $EVER $JPM